May 1st 2024
C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Case Presentation: A 63-Year-Old Woman with Relapsed-Refractory (R/R) Multiple Myeloma
December 22nd 2022Shaji Kumar, MD, presents a case of a 63-year-old woman with R/R multiple myeloma, shares his initial impression, and assess how clinical relapse impacts treatment decisions in patients with R/R multiple myeloma.
Watch
Single Agent Belantamab Mafodotin Shows Deep and Durable Responses in Final Analysis of RRMM Study
December 12th 2022In a final analysis of the DREAMM-2 study, results showed the rapid and durable responses of belantamab mafodotin continued in patients with relapsed/refractory multiple myeloma despite ocular toxicities.
Read More
Belantamb Mafodotin Shows PFS Benefit and Tolerable Safety in R/R Multiple Myeloma
December 12th 2022Compared with standard of care regimens for triple-class exposed, relapsed or refractory multiple myeloma, belantamb mafodotin with pomalidomide and dexamethasone extended progression-free survival without sacrificing safety.
Read More
PROs Data Support Use of Upfront Daratumumab Quadruplet for Transplant Eligible, Newly-Diagnosed MM
December 12th 2022Encouraging health-related quality of life benefit was demonstrated in for patients with transplant eligible, newly diagnosed multiple myeloma treated with a daratumumab quadruplet regimen.
Read More
Teclistamab, Daratumumab, and Lenalidomide Demonstrates Encouraging Safety in RRMM
December 10th 2022Results from the phase 1b MajesTEC-2 trial showed that teclistamab plus daratumumab and lenalidomide demonstrated potential for deep and durable responses in relapsed or refractory multiple myeloma.
Read More
Daratumumab With Bortezomib and Dexamethasone Improves Survival in RRMM
December 2nd 2022Patients with multiple myeloma administered daratumumab in combination with bortezomib and dexamethasone demonstrated improvements in overall survival compared with those given bortezomib and dexamethasone alone.
Read More
Clinical Commentary: Dose Reduction of Selinexor in Relapsed Patients With Multiple Myeloma
November 29th 2022At a live virtual event, Sumit Madan, MD, broke down the use of quadruplet therapies in the frontline setting for patients with multiple myeloma and how to care for patients when they relapse on treatment.
Read More
Efebera Discusses Different Regimens for Transplant-Eligible NDMM
November 23rd 2022During a Targeted Oncology case-based roundtable event, Yvonne A. Efebara, MD, MPH, discussed the role of triplet and quadruplet systemic therapies for newly diagnosed multiple myeloma and the use of autologous stem cell transplant.
Read More
FDA Requests Belantamab Mafodotin for R/R Multiple Myeloma Be Pulled From US Market
November 22nd 2022After an update from the phase 3 DREAMM-3 study the use of belantamab monotherapy for previously treated patients with relapsed or refractory multiple myeloma was pulled from US market authorization by request of the FDA.
Read More